Navigation Links
Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio

At the Disney’s Animal Kingdom the scientists and the theme park people have come together to set up an environmental storyline. In this are featured the latest scientific discoveries// from the Himalayan expedition to China and Nepal. They have showcased an array of exotic plant and animal species previously unknown to science. This was brought about by the two-month expedition known Expedition Everest. Some of the discoveries are a giant hornet which the local address as the Yak Killer, a beetle that feeds birds and small rodents to its young ones, jumping mouse and new species of amphibians, insects and ants.

The scientific journey into the mountains of Southwest China and Nepal also included Walt Disney Imagineering representatives who researched cultural beliefs related to the legend of the Yeti, a creature whose traditional role as "protector of the sacred" has been integral to conservation in the region. Those beliefs inspired the story of Expedition Everest – which includes selected findings from the two-month expedition included as part of the experience. Additionally, Jeff Corwin, host of Corwin's Quest, documented the Nepal expedition for broadcast on a special edition of his show Corwin's Quest: Realm of the Yeti, premiering Saturday, April 15, from 8-10 PM (ET/PT) on Discovery's Animal Planet. "By weaving the scientific discoveries and cultural research into the storyline of Expedition Everest, park visitors are provided with a unique opportunity to learn about the environmental heritage of this region.

The experience created by Disney is much more than just the physical thrills of a high-speed journey through the domain of the world's tallest mountain," said Dr. Russ Mittermeier, president of CI. "We are thrilled with Disney's dedication to conservation through their scientific and financial contributions to the expedition." Even though they faced rugged terrain and frigid temperatures not normally associated with new discoveri
'"/>




Page: 1 2 3 4

Related medicine news :

1. The Chemistry Of Sexual Attraction Between Male And Female Elephants
2. Valentines Day Attraction: Sale Of Condoms In School Proposed
3. Fatal Attraction: Cholesterol linked To Prostate cancer
4. Physical Attraction Alone May Not Boost Up Sales
5. Magnets in Commercial Products may Cause a Fatal Attraction
6. Commercialization of Biotech Discoveries, An Encouragement For Researchers
7. Dominant Discoveries and The Darker Side Of Methamphetamine Drug Addiction
8. Novel Discoveries For Treatment Of Stomach Cancer
9. Hearts Saved As Doctors Put Cutting Edge Discoveries to Use
10. Top UK Surgeon Who Loved Himalayas is Dead
Post Your Comments:
Breaking Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 1High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 3As Greenland melts 10423 1As Greenland melts 10423 2Research with wood ducks earns graduate student 2 national awards 10420 1
Other Medicine Technology:Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9